The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.

BACKGROUND HIV reverse transcriptase (RT) is a key target of anti-AIDS therapies. Structural studies of HIV-1 RT, unliganded and complexed with different non-nucleoside inhibitors (NNIs), have pointed to a common mode of binding and inactivation through distortion of the polymerase catalytic site by NNIs containing two hinged rings. The mode of binding of the TIBO family of inhibitors is of interest because these compounds do not fit the two-hinged-ring model. RESULTS The structure of HIV-1 RT complexed with 9-chloro-TIBO (R82913) has been determined at 2.6 A resolution. As reported for the lower resolution analysis of another TIBO compound, this inhibitor binds at the same site as other NNIs, but our higher resolution study reveals the Cl-TIBO is distorted from the conformation seen in crystals of the inhibitor alone. This allows Cl-TIBO to mimic the binding of NNIs containing two hinged rings. Inhibitor-protein interactions are again predominantly hydrophobic and the protein conformation corresponds to that seen in complexes with other tight-binding NNIs. CONCLUSIONS Although Cl-TIBO is chemically very different from other NNIs, it achieves remarkable spatial equivalence and shape complementarity with other NNIs on binding to RT. Comparison of the different RT-NNI complexes suggests modifications to the TIBO group of inhibitors which might enhance their binding and hence, potentially, their therapeutic efficacy.

[1]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution , 1995 .

[2]  D. Stuart,et al.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes. , 1996 .

[3]  R. Pauwels,et al.  Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[5]  Jones Ta,et al.  Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. , 1985, Methods in enzymology.

[6]  R. Pauwels.  Discovery of TIBO, a New Family of HIV-1-Specific Reverse Transcriptase Inhibitors , 1993 .

[7]  P. Mui,et al.  Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor. , 1992, Journal of medicinal chemistry.

[8]  J. Proudfoot,et al.  Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. , 1991, Journal of medicinal chemistry.

[9]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[10]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E A Merritt,et al.  Raster3D Version 2.0. A program for photorealistic molecular graphics. , 1994, Acta crystallographica. Section D, Biological crystallography.

[12]  D. Matthews,et al.  Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. , 1991, Science.

[13]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[14]  Erik De Clercq,et al.  HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase , 1993, Medicinal research reviews.

[15]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[16]  D W Rodgers,et al.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Richman.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents , 1993, Antimicrobial Agents and Chemotherapy.

[18]  A T Brünger,et al.  Slow-cooling protocols for crystallographic refinement by simulated annealing. , 1990, Acta crystallographica. Section A, Foundations of crystallography.

[19]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[20]  R T Walker,et al.  Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. , 1989, Biochemical and biophysical research communications.

[21]  J. Adams,et al.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.

[22]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Y. Satow,et al.  Structure of ribonuclease H phased at 2 A resolution by MAD analysis of the selenomethionyl protein. , 1990, Science.

[24]  W. Schäfer,et al.  Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. , 1993, Journal of medicinal chemistry.

[25]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[26]  R. Huber,et al.  Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .

[27]  K. Morikawa,et al.  Crystal structure of Escherichia coli RNase HI in complex with Mg2+ at 2.8 Å resolution: Proof for a single Mg2+‐binding site , 1993, Proteins.

[28]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[29]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[30]  D I Stuart,et al.  Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. , 1979, Journal of molecular biology.

[31]  B. Larder,et al.  Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.

[32]  R. Esnouf,et al.  Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution. , 1994, Journal of molecular biology.

[33]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.